| Literature DB >> 34406843 |
Hejia Guo1,2,3,4,5, Cuiping Li1,2,3,4, Xiaoping Su1,2,3,4, Xuanping Huang1,2,3,4,5.
Abstract
Objectives: This study was designed to identify a messenger RNA (mRNA) expression signature to predict survival in patients with oral squamous cell carcinoma (OSCC).Entities:
Keywords: bioinformatics analysis; mRNA signature; oral squamous cell carcinoma
Mesh:
Substances:
Year: 2021 PMID: 34406843 PMCID: PMC8403201 DOI: 10.1089/gtmb.2021.0066
Source DB: PubMed Journal: Genet Test Mol Biomarkers ISSN: 1945-0257
Clinical Characteristics of Oral Squamous Cell Carcinoma Patients Used in this Study
| Characteristic | Number of patients |
|---|---|
| Age (years) | 121/136 |
| <60/≥60 | |
| Sex | 180/77 |
| Male/female | |
| Grade | 39/159/51/2/6 |
| 1/2/3/4/NA | |
| Stage | 17/35/50/130/25 |
| I/II/III/IV/NA | |
| T | 26/74/57/79/21 |
| T1/T2/T3/T4/NA | |
| N | 95/38/88/2/34 |
| N0/N1/N2/N3/NA | |
| Vital status | 161/96 |
| Alive/dead |
NA, not available; T, tumor; N, lymph node status.
FIG. 1.Volcano plot of DEmRNAs. Red dots represent upregulated mRNAs and green dots represent downregulated mRNAs. FC, fold change; FDR, false discovery rate; DEmRNAs, differentially expressed mRNAs. Color images are available online.
The Detailed Information of Five Prognostic Messenger RNAs Significantly Associated with Overall Survival in Oral Squamous Cell Carcinoma
| Gene symbol | Chromosome | Coefficient[ | HR[ | Regulation[ | |
|---|---|---|---|---|---|
| HOXA1 | Chr7:27092993–27096000 | 0.0008 | 0.1979 | 1.2188 | Upregulated |
| CELSR3 | Chr3:48636463–48662886 | 0.0011 | −0.1727 | 0.8414 | Upregulated |
| HIST1H3J | Chr6:27890315–27890826 | 0.0008 | 0.2235 | 1.2504 | Upregulated |
| ZFP42 | Chr4:187994044–188005046 | 0.0007 | 0.0868 | 1.0906 | Upregulated |
| ASCL4 | Chr12:107774385–107776644 | 0.0009 | −0.2690 | 0.7641 | Upregulated |
Derived from the univariable Cox proportional hazards regression analysis in 257 OSCC patients.
Derived from the multivariate Cox proportional hazards regression analysis in 257 OSCC patients.
Type of regulation in OSCC compared to normal tissue.
HR, hazard ratio; OSCC, oral squamous cell carcinoma.
FIG. 2.5-mRNA risk score analysis of 257 OSCC patients. (A) 5-mRNA risk score distribution. (B) Patient survival status along with risk score. The dotted line represents the 5-mRNA signature cutoff dividing patients into low-risk and high-risk groups. (C) Heat map of 5-mRNA expression profiles of OSCC patients. (D) Kaplan–Meier curves for low- and high-risk patients. OSCC, oral squamous cell carcinoma. Color images are available online.
Univariate and Multivariate COX Regression Analyses of the Messenger RNA Signature and Survival
| Variables | Unfavorable/favorable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | ||||
| Risk score | High/low | 3.497 (2.279–5.677) | 3.864E-8 | 3.506 (2.214–5.554) | 8.992E-8 |
| Age | ≥60/<60 | 1.020 (1.002–1.038) | 0.026 | 1.378 (0.917–2.072) | 0.123 |
| Sex | Male/female | 1.220 (0.802–1.856) | 0.352 | ||
| Grade | G3+G4/G1+G2 | 1.061 (0.819–1.373) | 0.654 | ||
| Clinical stage | III+IV/I+II | 1.466 (1.030–2.087) | 0.034 | ||
| Clinical-T | T3+T4/T1+T2 | 1.483 (1.096–2.006) | 0.011 | 1.365 (0.985–1.892) | 0.062 |
| Clinical-N | N1+N2/N0 | 1.289 (0.969–1.716) | 0.082 | ||
CI, confidence interval.
FIG. 3.The ROC curve for the 5-mRNA signature representing 3-year prediction. ROC, receiver operating characteristic. Color images are available online.
Correlation of Risk Score and Clinicopathological Characteristics in Oral Squamous Cell Carcinoma Patients
| Characteristic | Number of patients | χ2 | ||
|---|---|---|---|---|
| Low risk | High risk | |||
| Total patients | 128 | 129 | ||
| Age (years) | ||||
| <60 | 58 (60.3) | 63 (60.7) | 0.320 | 0.571 |
| ≥60 | 70 (67.7) | 66 (68.3) | ||
| Sex | ||||
| Male | 93 (89.6) | 87 (90.4) | 0.832 | 0.362 |
| Female | 35 (38.4) | 42 (38.6) | ||
| Grade | ||||
| G1+G2 | 87 (98.6) | 111 (99.4) | ||
| G3+G4 | 37 (26.4) | 16 (26.6) | 11.951 | 0.002 |
| Gx | 4 (3) | 2 (3) | ||
| Clinical-stage | ||||
| I+II | 36 (25.9) | 16 (26.1) | ||
| III+IV | 78 (89.6) | 102 (90.4) | 11.249 | 0.004 |
| NA | 14 (12.5) | 11 (12.5) | ||
| Clinical-T | ||||
| T1+T2 | 64 (49.8) | 36 ( (50.2) | ||
| T3+T4 | 52 (67.7) | 84 (68.3) | 15.794 | 0.000 |
| Tx | 12 (10.5) | 9 (10.5) | ||
| Clinical-N | ||||
| N0 | 54 (47.3) | 41 (47.7) | ||
| N1+N2 | 53 (62.8) | 73 (63.2) | 6.009 | 0.050 |
| Nx | 20 (16.9) | 14 (17.1) | ||
NA, not available; T, tumor status; N, lymph node status.
FIG. 4.The first 20 genes network. The first 20 genes of the MMC method were chosen using CytoHubba plug-in. The more forward ranking is represented by a redder color. Color images are available online.
Significantly Enriched Gene Ontology Terms and Kyoto Encyclopedia of Genes and Genomes Pathways for Top 20 Hub Genes in the Protein–Protein Interaction Networks
| Description | Number of enriched genes | ||
|---|---|---|---|
| GO terms | |||
| GO:0007062 | Sister chromatid cohesion | 14 | 2.08E-25 |
| GO:0051301 | Cell division | 17 | 8.23E-25 |
| GO:0031145 | Anaphase-promoting complex-dependent catabolic process | 8 | 1.87E-12 |
| GO:0051437 | Positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition | 7 | 1.82E-10 |
| GO:0007059 | Chromosome segregation | 5 | 9.11E-07 |
| GO:0008283 | Cell proliferation | 7 | 2.20E-06 |
| KEGG terms | |||
| hsa04110 | Cell cycle | 9 | 3.88E-13 |
| hsa04115 | p53 signaling pathway | 3 | 0.0040 |
| hsa04068 | FoxO signaling pathway | 3 | 0.0153 |
| hsa05203 | Viral carcinogenesis | 3 | 0.0340 |
GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
FIG. 5.Enrichment plots of the five signature-related mRNAs from GSEA. GSEA, gene set enrichment analysis. Color images are available online.
FIG. 6.qRT-PCR results of the five signature-related mRNAs. Expression of these mRNAs was normalized against GAPDH expression. *p < 0.05; **p < 0.001. qRT-PCR, quantitative real-time polymerase chain reaction.